Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer

BACKGROUND: Taxane, carboplatin and trastuzumab (TCH) is an effective neoadjuvant regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer with high pathologic complete response (pCR) rate. The KATHERINE trial changes the outlook for high-risk HER2-positive breast cancer, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yifan, Wu, Siyu, Zhang, Ying, Li, Jianwei, Mo, Miao, Shao, Zhimin, Liu, Guangyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217668/
https://www.ncbi.nlm.nih.gov/pubmed/34168999
http://dx.doi.org/10.3389/fonc.2021.686591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217668/
https://www.ncbi.nlm.nih.gov/pubmed/34168999
http://dx.doi.org/10.3389/fonc.2021.686591

Ejemplares similares